Biocompatibility Testing of Medical Catheters: Standards, Methods, and Evaluation Framework

Biocompatibility testing of medical catheters is a mandatory safety evaluation process that verifies whether catheter materials and their extractable substances cause adverse biological responses when in contact with human tissue, mucosa, or blood. Conducted in accordance with the ISO 10993 series (and the equivalent GB/T 16886 series), this testing covers cytotoxicity, sensitization, irritation, systemic toxicity, and hemocompatibility, forming the scientific basis for regulatory submission and clinical safety assurance.

Technical Overview

Medical catheters are among the most widely used device categories in clinical practice, ranging from urinary catheters and central venous catheters to endotracheal tubes and interventional balloon catheters. Because these devices come into direct or indirect contact with blood, mucosal membranes, tissues, or breached body surfaces for extended durations, their biological safety must be systematically demonstrated before market release.

Biocompatibility testing evaluates the interaction between the final catheter product—in its final form, final manufacturing condition, and sterilization state—and living biological systems. The evaluation framework is defined by ISO 10993-1 (Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process), which classifies devices by nature of body contact (surface devices, external communicating devices, implant devices) and contact duration (limited exposure ≤ 24 h, prolonged exposure 24 h to 30 days, permanent contact > 30 days). In China, the GB/T 16886 series adopts the same technical structure and is referenced by NMPA device registration requirements.

The testing strategy is not a fixed checklist but a risk-based process that considers material composition, processing aids, sterilization residuals, leachables, and clinical use conditions. Accredited third-party laboratories typically perform the experimental work, while manufacturers are responsible for the biological evaluation plan and final risk assessment documentation.

Testing Samples

Final Product Samples

Testing must be performed on the finished catheter in its final configuration, including all components that contact the patient: the catheter shaft, balloon, coating, hub, and connector surfaces. Samples must be representative of the sterilized, market-ready product, since sterilization methods such as ethylene oxide (EtO) or gamma irradiation can generate residuals or alter polymer surface chemistry.

Sample Categories by Contact Type

• Mucosal membrane contact catheters: urinary (Foley) catheters, nasogastric tubes, endotracheal tubes — evaluated as surface or external communicating devices depending on duration.
• Indirect blood contact catheters: hemodialysis catheters, extracorporeal circuit tubing, IV administration sets — tested for hemocompatibility and systemic effects.
• Direct circulating blood contact catheters: central venous catheters, peripherally inserted central catheters (PICC), arterial catheters, PTCA/PTA catheters, guide catheters — requiring full hemocompatibility assessment.
• Tissue and bone contact catheters: epidural catheters, neurosurgical drainage catheters, wound drainage catheters — requiring implantation and local effect evaluation.

Test Extracts and Extract Conditions

For most in vitro and in vivo tests, sample extracts are prepared according to ISO 10993-12 using both polar media (e.g., saline, culture medium with serum) and non-polar media (e.g., sesame oil). Standard extraction conditions include 37 °C for 72 hours (most physiologically representative), 50 °C for 72 hours, 70 °C for 24 hours, or 121 °C for 1 hour when accelerated exhaustive extraction is needed. The standard surface-area-to-volume ratio for catheter tubing is 6 cm²/mL, or a mass ratio of 0.2 g/mL when surface area cannot be determined.

Testing Items

Based on the ISO 10993-1 decision matrix, the following endpoints are commonly required for medical catheters:

• Cytotoxicity (ISO 10993-5): evaluates cell death, growth inhibition, and morphological changes in mammalian cell cultures — a baseline test for all catheter types.
• Sensitization (ISO 10993-10): assesses delayed-type hypersensitivity potential, typically via guinea pig maximization test (GPMT), Buehler test, or LLNA (local lymph node assay).
• Irritation or intracutaneous reactivity (ISO 10993-23): determines local inflammatory response, usually via rabbit intracutaneous injection of extracts or direct mucosal application.
• Acute systemic toxicity (ISO 10993-11): detects harmful effects from a single exposure via intravenous or intraperitoneal injection of extracts in mice.
• Material-mediated pyrogenicity: ensures the product does not induce febrile response, often evaluated alongside the rabbit pyrogen test or justified through an endotoxin limit strategy.
• Hemocompatibility (ISO 10993-4): mandatory for blood-contacting catheters; includes hemolysis testing, thrombogenicity, coagulation, platelet activation, and complement activation as applicable.
• Genotoxicity (ISO 10993-3): Ames bacterial reverse mutation assay, chromosomal aberration test, and mouse micronucleus test — required for prolonged and permanent contact devices or when novel materials, coatings, or drug components are present.
• Subacute and subchronic toxicity (ISO 10993-11): repeated-dose systemic studies for devices with prolonged contact.
• Local effects after implantation (ISO 10993-6): histopathological evaluation of tissue response at implant sites, relevant for catheters residing in tissue or vascular pathways.

For catheters carrying surface modifications such as hydrophilic coatings, antimicrobial agents, or drug combinations, additional chemical characterization (ISO 10993-18) and toxicological risk assessment (ISO 10993-17) are generally required to complete the biological evaluation file.

Testing Methods

The choice of method depends on the device's contact classification and the specific endpoint being evaluated:

• Cytotoxicity — MEM elution method: L929 mouse fibroblast cells are exposed to sample extracts for 24–48 hours, and viability is quantified by qualitative morphology scoring or quantitative assays such as MTT, XTT, or neutral red uptake. A viability value above 70% relative to the negative control indicates a pass.
• Direct contact and agar diffusion methods: alternatives to elution for evaluating leachable toxicity from catheter surfaces where extract preparation is impractical.
• Sensitization — GPMT: guinea pigs receive intradermal induction with extract plus Freund's adjuvant, followed by topical challenge; erythema and edema are scored against controls.
• Intracutaneous reactivity: 0.2 mL of polar and non-polar extracts are injected intradermally at multiple sites on rabbit backs, and irritation is scored at 24, 48, and 72 hours.
• Hemolysis testing: indirect hemolysis exposes rabbit or human blood to sample extracts, while direct hemolysis places blood in direct contact with the catheter material; the hemolysis index is calculated from released hemoglobin. A result below 5% is typically considered non-hemolytic.
• Thrombogenicity: in vitro dynamic flow-loop models or in vivo venous implantation assess clot formation, with ASTM and ISO methodologies referenced for flow conditions.
• Systemic toxicity: mice are dosed intravenously with polar extracts and observed for 72 hours for mortality, clinical signs, and body weight change.
• Genotoxicity: the Ames test uses multiple Salmonella typhimurium and E. coli strains with and without metabolic activation; the in vitro micronucleus or chromosomal aberration test complements it for clastogenicity assessment.

All testing must use appropriate negative controls (e.g., high-density polyethylene reference material) and positive controls (e.g., ZDEC polyurethane for cytotoxicity) to demonstrate assay sensitivity. Sterility and endotoxin considerations may also apply when animal testing is involved.

Applications

Biocompatibility test data serve multiple regulatory and quality purposes across the catheter product lifecycle:

• Market registration submissions: NMPA registration dossiers in China require a complete biological evaluation report based on GB/T 16886; FDA 510(k) and PMA submissions reference ISO 10993 biological evaluation summaries; EU MDR conformity assessment demands biocompatibility evidence under the state of the art.
• New product development: screening candidate polymers, plasticizers, coatings, adhesives, and sterilization methods before design freeze.
• Change control: any material supplier change, formulation modification, manufacturing process change, or sterilization method change requires biological re-evaluation to determine whether retesting is needed.
• Benchmarking and supplier qualification: comparing raw material lots or comparing a new catheter design against a clinically established predicate.
• Supporting chemical characterization programs: linking extractables/leachables data to toxicological endpoints when experimental testing can be reduced through justified risk assessment.

FAQ

Which tests are mandatory for a blood-contacting catheter?

For catheters contacting circulating blood for prolonged duration, the core set typically includes cytotoxicity, sensitization, intracutaneous irritation, acute systemic toxicity, hemolysis, thrombogenicity or a justified hemocompatibility panel, and often genotoxicity and implantation studies depending on the risk assessment.

How many samples are required for testing?

Sample quantity depends on the test portfolio: cytotoxicity typically needs one complete catheter or representative sections per extraction condition, irritation requires sufficient material to prepare both polar and non-polar extracts at standard ratios, and in vivo studies may require multiple production lots or larger sample volumes. Accredited third-party laboratories usually request 3 to 10 sterile final product units plus retain samples.

What is the typical project timeline?

Individual short-term tests (cytotoxicity, irritation, hemolysis) are generally completed within 2 to 4 weeks including extraction. Sensitization studies require approximately 4 to 6 weeks, genotoxicity batteries around 8 to 12 weeks, and implantation studies range from 2 weeks to several months depending on the implantation period selected.

Can a manufacturer rely on supplier biocompatibility data?

Supplier raw-material data alone is usually insufficient, because extrusion, molding, bonding, coating, printing, and sterilization all influence the biological response of the final catheter. Testing must be performed on the finished, sterilized device, although material data may support the written risk assessment.

How does ISO 10993 testing differ from GB/T 16886 testing?

The GB/T 16886 series is technically aligned with ISO 10993 and shares the same classification logic and endpoints. Minor differences exist in implementation details and national acceptance practices, so manufacturers targeting multiple markets should confirm current editions with accredited third-party laboratories before finalizing the test plan.